Dr. Mason Discusses the PROTECT Study in Localized Prostate Cancer
Malcom Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses the significance of the PROTECT study in patients with localized prostate cancer.<br /> ​
Malcom Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses the significance of the PROTECT study in patients with localized prostate cancer.
Astonishingly, after a median follow-up of 10 years, the prostate cancer mortality rate, which was the primary endpoint of the study, was only 1%, Mason says.
Digging a little deeper, Mason says, the overall mortality was only 10% at 10 years. But, if you look at clinical disease progression, there was a difference. Curative treatments, including surgery or radiotherapy, do reduce the likelihood of disease progression by about half. That is a big effect, however, this is a phenomenon that only affects a minority of men, Mason says.
The results of PROTECT should not be used as an argument to say we should not be treating men with deferred treatment, as most men do not require treatment. However, whether or not it is right to defer treatment for an individual man depends on the patient’s perception of the risk of disease progression versus the side effects of immediate treatment with surgery or radiotherapy.
First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC
September 18th 2023A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.
Listen
Need for Systemic Therapy Remains in Sarcoma
November 27th 2023In an interview with Targeted Oncology, Lisa B. Ercolano, MD, discussed the evolving treatment landscape for sarcomas and underscored the pivotal role of molecular profiling, while addressing the need for more efficacious systemic therapies.
Read More
BRUIN MCL-321 Trial Evaluates Pirtobrutinb Monotherapy in MCL
November 20th 2023In an interview with Targeted Oncology, Michael Wang, MD, discussed the rationale of the phase 3 study and how positive results from this trial may further shape the mantle cell lymphoma treatment landscape.
Read More
